Spyre Therapeutics (SYRE) Non-cash Items (2015 - 2022)

Spyre Therapeutics has reported Non-cash Items for 8 years, with the latest figure at $4.1 million in Q4 2022.

• For the quarter ending Q4 2022, Non-cash Items rose 1145.81% year-over-year to $4.1 million; the trailing twelve-month figure through Dec 2022 stood at $4.1 million (up 1145.81% YoY), and the FY2022 full-year result was $4.1 million, up 1145.81% from the prior year.
• Non-cash Items for Q4 2022 stood at $4.1 million, up from $328000.0 in the prior quarter.
• The five-year high for Non-cash Items was $4.8 million in Q4 2018, with the low at $328000.0 in Q4 2021.
• Historically, Non-cash Items has averaged $3.3 million across 5 years, with a median of $3.8 million in 2020.
• Annual changes were most pronounced in 2021 — Non-cash Items plunged 91.34% — and 2022, when it surged 1145.81%.
• Spyre Therapeutics' Non-cash Items stood at $4.8 million in 2018, then dropped by 24.09% to $3.6 million in 2019, then increased by 4.01% to $3.8 million in 2020, then sank by 91.34% to $328000.0 in 2021, then surged by 1145.81% to $4.1 million in 2022.
• The last three Non-cash Items figures came in at $4.1 million (Q4 2022), $328000.0 (Q4 2021), and $3.8 million (Q4 2020), per Business Quant data.